Profusa Granted Conditional Nasdaq Listing Extension and Transfer

Profusa ( (PFSA) ) has shared an update.

On May 6, 2026, Profusa, Inc. received a decision from a Nasdaq Hearings Panel granting the company an exception to continue listing, conditioned on meeting interim milestones and regaining compliance with bid price and stockholders’ equity requirements by July 6, 2026. The determination also allows Profusa to transfer its securities from the Nasdaq Global Market to the Nasdaq Capital Market, while requiring prompt disclosure of significant events that could affect its ability to satisfy the terms of the exception.

Profusa said it is evaluating the panel’s conditions and plans to take actions aimed at demonstrating full compliance with Nasdaq listing criteria within the specified timeframe, though it cautioned that there is no assurance it will succeed. The company’s continued presence on Nasdaq’s Capital Market tier is therefore contingent on executing its compliance plan, a factor that may influence investor confidence and access to capital as it advances its digital health biosensing platform.

More about Profusa

Profusa, Inc. is a Berkeley, California-based commercial-stage digital health company developing tissue-integrated, injectable biosensors that continuously monitor an individual’s biochemistry and transmit medical-grade data for personal and clinical use. Its platform combines long-lasting, affordable biosensors with an intelligent data system to deliver personalized biochemical signatures for clinicians, and its product portfolio includes technologies marketed under the LUMEE and PROFUSA trademarks across multiple global regions.

The company is led by scientific founders, an experienced management team and a board of directors focused on advancing next-generation continuous monitoring solutions in key healthcare markets. Profusa positions itself at the intersection of biosensing and data-driven medicine, targeting applications where continuous, reliable biochemical data can support diagnosis, treatment decisions and long-term disease management.

Average Trading Volume: 5,109,236

Technical Sentiment Signal: Sell

Current Market Cap: $2.16M

For detailed information about PFSA stock, go to TipRanks’ Stock Analysis page.